Argent Capital Management LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 294.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 196,214 shares of the biopharmaceutical company’s stock after buying an additional 146,530 shares during the period. Argent Capital Management LLC’s holdings in Gilead Sciences were worth $12,756,000 at the end of the most recent reporting period.
Other institutional investors also recently added to or reduced their stakes in the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its stake in shares of Gilead Sciences by 95.7% during the fourth quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock worth $34,658,000 after purchasing an additional 271,000 shares in the last quarter. Chilton Capital Management LLC lifted its stake in shares of Gilead Sciences by 3.5% during the fourth quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 555 shares in the last quarter. Nicholas Company Inc. lifted its stake in shares of Gilead Sciences by 2.7% during the fourth quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock worth $31,697,000 after purchasing an additional 13,500 shares in the last quarter. Sectoral Asset Management Inc lifted its stake in shares of Gilead Sciences by 59.6% during the fourth quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock worth $26,577,000 after purchasing an additional 158,750 shares in the last quarter. Finally, AIMZ Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 39.9% during the fourth quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock worth $3,361,000 after purchasing an additional 15,333 shares in the last quarter. 78.78% of the stock is owned by institutional investors.
A number of research analysts have commented on GILD shares. ValuEngine cut Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 13th. Mizuho restated a “buy” rating and set a $88.00 price objective on shares of Gilead Sciences in a research note on Tuesday, February 26th. JPMorgan Chase & Co. restated a “buy” rating on shares of Gilead Sciences in a research note on Thursday, March 7th. Piper Jaffray Companies set a $75.00 price objective on Gilead Sciences and gave the stock a “hold” rating in a research note on Thursday, March 7th. Finally, BMO Capital Markets assumed coverage on Gilead Sciences in a research note on Thursday, March 14th. They set an “outperform” rating and a $78.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $79.54.
In other news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total transaction of $173,178.00. Following the completion of the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at $3,691,898.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now directly owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,602 shares of company stock valued at $1,863,445. 0.20% of the stock is owned by corporate insiders.
Shares of Gilead Sciences stock opened at $66.78 on Thursday. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The stock has a market capitalization of $83.31 billion, a P/E ratio of 10.86, a PEG ratio of 0.80 and a beta of 1.09. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. The firm had revenue of $5.28 billion during the quarter, compared to analyst estimates of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. Gilead Sciences’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.48 earnings per share. Equities research analysts anticipate that Gilead Sciences, Inc. will post 6.6 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.77%. The ex-dividend date is Thursday, June 13th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
ILLEGAL ACTIVITY WARNING: “Argent Capital Management LLC Buys 146,530 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2019/06/13/argent-capital-management-llc-buys-146530-shares-of-gilead-sciences-inc-nasdaqgild.html.
Gilead Sciences Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: Dividend
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.